A FASTER OPTION FOR RECEIVING TECENTRIQ® (atezolizumab): LESS TIME FOR TREATMENT, MORE TIME FOR YOU*



A CHOICE FOR YOU AND YOUR DOCTOR


TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs) injections and TECENTRIQ infusions (which are given into your vein through an intravenous, or IV, line) are thought to work the same way and have similar side effects. In fact, a trial of 371 adults with advanced non-small cell lung cancer (NSCLC) compared TECENTRIQ HYBREZA injections to TECENTRIQ infusions and found that there were no major differences between the 2 treatments. The trial measured the amount of medicine in the bloodstream (which is commonly done to ensure that the injection works like the infusion). This means you and your doctor can decide together which treatment option is better for you.

WHAT IS TECENTRIQ HYBREZA?

TECENTRIQ HYBREZA is a faster* way to receive TECENTRIQ immunotherapy treatment. It is administered by your healthcare provider in your thigh as a **subcutaneous injection**-which means it is given under the skin. TECENTRIQ HYBREZA is approved to treat the same adult patients as the IV infusion form of TECENTRIQ. Read more about approved uses on page 2.

DESIGNED WITH YOUR TIME IN MIND

TECENTRIQ HYBREZA injections are preferred by more adult patients compared to TECENTRIQ infusions, primarily because of less time spent in the clinic. What would you do with less time in the clinic?[†]



IMPORTANT SAFETY INFORMATION

Who should not receive TECENTRIQ HYBREZA?

Do not receive TECENTRIQ HYBREZA if you are allergic to hyaluronidase or any of the ingredients in TECENTRIQ HYBREZA

What is the most important information about TECENTRIQ HYBREZA?

TECENTRIQ HYBREZA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more

than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Please see pages 2-3 and full <u>Prescribing Information</u> and <u>Medication Guide</u> for indications and additional Important Safety Information.



atezolizumab/hyaluronidase-tqjs subcutaneous INJECTION 1875 mg/30,000 units

WHAT IS TECENTRIQ HYBREZA?

TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) is a prescription medicine used to treat:

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

- TECENTRIQ HYBREZA may be used alone as a treatment for your lung cancer:
- to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy, and
- you have stage 2 to stage 3A NSCLC (talk to your healthcare provider about what these stages mean), and
- your cancer tests positive for "PD-L1".
- TECENTRIQ HYBREZA may be used alone as your first treatment when your lung cancer:
- has spread or grown, and
- your cancer tests positive for "high PD-L1", and
- your tumor does not have an abnormal "EGFR" or "ALK" gene.
- TECENTRIQ HYBREZA may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer:
- has spread or grown, **and**
- is a type called "non-squamous NSCLC", **and**
- your tumor does not have an abnormal "EGFR" or "ALK" gene.

• TECENTRIQ HYBREZA may be used with the medicines paclitaxel protein-bound and carboplatin as your first treatment when your lung cancer:

- has spread or grown, **and**
- is a type called "non-squamous NSCLC", and
- your tumor does not have an abnormal "EGFR" or "ALK" gene.
- TECENTRIQ HYBREZA may be used alone when your lung cancer:
 has spread or grown, and
- you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
- If your tumor has an abnormal "EGFR" or "ALK" gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

Adults with a type of lung cancer called small cell lung cancer (SCLC). TECENTRIQ HYBREZA may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment when your lung cancer:

• is a type called "extensive-stage small cell lung cancer," which means that it has spread or grown.

Adults with a type of liver cancer called hepatocellular carcinoma (HCC). TECENTRIQ HYBREZA may be used with the medicine bevacizumab when your liver cancer:

- has spread or cannot be removed by surgery, and
- you have not received other medicines by mouth or injection through your vein (IV) to treat your cancer.

Adults with a type of skin cancer called melanoma. TECENTRIQ HYBREZA may be used with the medicines cobimetinib and vemurafenib when your melanoma:

- has spread to other parts of the body or cannot be removed by surgery, **and**
- has a certain type of abnormal "BRAF" gene. Your healthcare provider will perform a test to make sure this TECENTRIQ HYBREZA combination is right for you.
- It is not known if TECENTRIQ HYBREZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

• chest pain

- Lung problemscough
- shortness of breath

Intestinal problems

- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness

Liver problems

- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)

Hormone gland problems

- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual

Kidney problems

- decrease in your amount of urine
- blood in your urine

Skin problems

- rash
- itching
- skin blistering or peeling

swollen lymph nodes

Problems can also happen in other organs.

- These are not all of the signs and symptoms of immune system problems that can happen with TECENTRIQ HYBREZA. Call or see your healthcare provider right away for any new or worse signs or symptoms, including:
- Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

- chills or shakingitching or rash
- dizziness
 fooling like
 - feeling like passing out
 fever
- flushingshortness of breath or wheezing
- back or neck pain

TECENTRIQ Hybreza

atezolizumab/hyaluronidase-tqjs subcutaneous INJECTION 1875 mg/30,000 units

• bleeding or bruising more easily

• dark urine (tea colored)

- urinating more often than usual
- hair loss

than normal

- feeling cold
- constipation
- your voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

painful sores or ulcers in mouth

or nose, throat, or genital area

fever or flu-like symptoms

- swelling of your ankles
- loss of appetite

IMPORTANT SAFETY INFORMATION (CONTINUED)

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with TECENTRIQ HYBREZA. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from **becoming more serious.** Your healthcare provider will check you for these problems during your treatment with TECENTRIQ HYBREZA. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with TECENTRIQ HYBREZA if you have severe side effects.

Before vou receive TECENTRIQ HYBREZA, tell vour healthcare provider about all of your medical conditions, including if you:

- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to your chest area
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. TECENTRIQ HYBREZA can harm vour unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TECENTRIQ HYBREZA. Females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with TECENTRIQ HYBREZA.
- You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of TECENTRIQ HYBREZA.
- are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ HYBREZA passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ HYBREZA.

Tell your healthcare provider about all the medicines you take,

including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of TECENTRIQ HYBREZA when used alone include:

- feeling tired or weak • muscle or bone pain
- shortness of breath

decreased appetite

- cough
- The most common side effects observed with TECENTRIQ and may be experienced with TECENTRIQ HYBREZA are shown below.

The most common side effects of TECENTRIQ when used alone as the first treatment for NSCLC include:

feeling tired or weak

The most common side effects of TECENTRIQ when used alone in NSCLC that has spread or grown include:

- feeling tired or weak
- shortness of breath

- cough
- muscle or bone pain
- decreased appetite

- The most common side effects of TECENTRIQ when used in NSCLC with bevacizumab, paclitaxel, and carboplatin include:
- numbness, pain, tingling, or constipation • decreased appetite
- burning in your hands or feet
- feeling tired or weak
- hair loss
- muscle or bone pain
- nausea
- diarrhea
- The most common side effects of TECENTRIQ when used in nonsquamous NSCLC with paclitaxel protein-bound and carboplatin include:
- feeling tired or weak
- nausea
- diarrhea
 - muscle or bone pain
 - constipation
 - numbness, pain, tingling, or
- shortness of breath decreased appetite

• joint pain

• rash

couah

high blood pressure

• cough

hair loss

vomiting

decreased appetite

constipation

vomiting

- rash
- The most common side effects of TECENTRIQ when used in SCLC with carboplatin and etoposide include:
- feeling tired or weak

burning in your hands or feet

- nausea
- hair loss
- The most common side effects of TECENTRIQ when used in HCC with
- bevacizumab include: • high blood pressure
- feeling tired or weak
- too much protein in the urine

The most common side effects of TECENTRIQ when used in melanoma with cobimetinib and vemurafenib include:

- skin rash
- joint, muscle, or bone pain
- feeling tired or weak
- liver injury
- fever nausea
- low thyroid hormone levels
- sunburn or sun sensitivity

TECENTRIQ HYBREZA may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of TECENTRIQ HYBREZA. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of TECENTRIQ HYBRE7A.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information and Medication **<u>Guide</u>** for additional Important Safety Information.





- itching
- swelling of legs or arms
- mouth swelling (sometimes with sores)

TECENTRIQ HYBREZA: HELPFUL TIPS FOR YOUR TREATMENT DAYS



WEAR SHORTS, A DRESS, OR LOOSE PANTS

You may want to put on clothing that makes it easy to access your thigh, because that is where TECENTRIQ HYBREZA injections are given.



STAY WARM

Some people feel cold during their injection, so you may want to bring a warm blanket.



AVOID APPLYING LOTION

Wait until after your appointment to apply any lotion to your thigh, to make sure your skin is clean and prepared for your injection.



TAKE DEEP BREATHS

If you are nervous about needles, looking away from the injection site and taking slow, deep breaths may help you feel calm during the injection.



ENTERTAIN YOURSELF

You may also want to use this time to read a magazine or newspaper, scroll through social media, or watch a short video on your phone.



KEEP TRACK OF WHERE YOUR INJECTION IS GIVEN

While it's fresh in your mind, jot down which thigh you had your injection in so you can alternate the area next time.

START A CONVERSATION WITH YOUR DOCTOR ABOUT TECENTRIQ HYBREZA

TECENTRIQ Hybreza[™] atezolizumab/hyaluronidase-tqjs subcutaneous injection 1875 mg/30,000 units

ABOUT FINANCIAL OPTIONS: ACCESSING TECENTRIQ HYBREZA

There may be options that may help you afford your TECENTRIQ HYBREZA, no matter what type of health insurance you have.

THE GENENTECH ONCOLOGY CO-PAY ASSISTANCE PROGRAM

The Genentech Oncology Co-pay Program helps you if you have commercial health insurance and meet other eligibility criteria.*



No physical card needed; patients simply need their Member ID. To learn more about the Genentech Oncology Co-pay Assistance Program, call (855) MY-COPAY (855-692-6729) or visit <u>copayassistancenow.com</u>

*The Co-pay Program is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. Patients using Medicare, Medicaid or any other federal or state government program (collectively, "Government Programs") to pay for their Genentech medicine are not eligible.

Under the Program, the patient may pay a co-pay. The final amount owed by a patient may be as little as \$0 for the Genentech medicine (see Program specific details). The total patient out-of-pocket cost is dependent on the patient's health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient's out-of-pocket expenses for the cost associated with the Genentech medicine.

All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. No party may seek reimbursement for all or any part of the benefit received through the Program. The Program is intended for the patient. Only the patient using the Program were treinds made available through the Program is not intended for third parties who reduce the available to the patient or take a portion for their own purposes. Patients with health plans that redirect Genenetch Program assistance intended for patient out- of-pocket costs may be subject to alternate Program benefit structures. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.

Additional terms and conditions apply. Please visit the Co-pay Program website for the full list of Terms and Conditions.

INDEPENDENT CO-PAY ASSISTANCE FOUNDATION

If you need help with the co-pay for your TECENTRIQ HYBREZA, Genentech Access Solutions can refer you to an independent co-pay assistance foundation.⁺ Independent co-pay assistance foundations help patients with public or commercial health insurance.

[†]Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help you. We can only refer you to a foundation that supports your disease state. This information is provided as a resource for you. Genentech does not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help you.

THE GENENTECH PATIENT FOUNDATION

The Genentech Patient Foundation[‡] provides free TECENTRIQ HYBREZA to people who need it.

⁺If you have health insurance, you should try to get other types of financial assistance, if available. You also need to meet income requirements. If you do not have insurance, or if your insurance does not cover your TECENTRIQ HYBREZA, you must meet a different set of income requirements. Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

SIGN UP FOR GENENTECH ACCESS SOLUTIONS

To enroll in Genentech Access Solutions, simply fill out the Patient Consent Form. Your doctor will have to fill out a separate form. We can begin helping you once we receive both forms. You can find the Patient Consent Form at <u>Genentech-Access.com/PatientConsent</u>, or your doctor might give you a copy of the form to fill out.

For more information visit <u>TECENTRIQ.com/ACCESS</u> or call (877) GENENTECH/(877) 436-3683 to get started.

Please see pages 2-3 and full <u>Prescribing Information</u> and <u>Medication Guide</u> for indications and additional Important Safety Information.



atezolizumab/hyaluronidase-tqjs subcutaneous INJECTION 1875 mg/30,000 units



Genentech A Member of the Roche Group © 2024 Genentech USA, Inc. All rights reserved. M-US-00020828(v1.0)